ESMO 2022 | Resistance mechanisms associated with the use of ADCs in UC

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of the limited understanding of resistance mechanisms to antibody-drug conjugates (ADCs) in patients with urothelial carcinoma, including down-regulation of nectin-4 in response to therapy with enfortumab vedotin. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.